Abstract

Despite numerous studies on multiple sclerosis (MS) and understanding many aspects of this disease, researchers still struggle to find proper biomarkers that facilitate diagnosis; prognosis and monitoring of treatment efficacy in MS. MicroRNAs (miRNAs) are considered as endogenous, comparatively stable and small non-coding RNAs involved in various biological and pathological signaling pathways. Interestingly, miRNAs have been emerged as a potential biomarker for monitoring novel therapies in MS patients. In this review, we described the miRNAs alteration in the MS patients as well as their altered expression in patients under common MS therapies.

摘要

尽管对多发性硬化症 (MS) 进行了大量研究并了解这种疾病的许多方面，但研究人员仍然难以找到有助于诊断的适当生物标志物。MS的预后和治疗效果监测。MicroRNAs (miRNAs) 被认为是内源性的、相对稳定的、小的非编码 RNA，参与各种生物和病理信号通路。有趣的是，miRNA 已成为监测 MS 患者新疗法的潜在生物标志物。在这篇综述中，我们描述了 MS 患者的 miRNA 改变以及它们在常见 MS 治疗下患者的表达改变。